Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Aripiprazole in the Treatment of Bipolar Depression
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Cambridge Health Alliance
- Target Recruit Count
- 20
- Registration Number
- NCT00226317
- Locations
- 🇺🇸
Cambridge Health Alliance, Cambridge, Massachusetts, United States
The Effects of Aripiprazole on Patients With Metabolic Syndrome
- Conditions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- New Mexico VA Healthcare System
- Target Recruit Count
- 27
- Registration Number
- NCT00224822
- Locations
- 🇺🇸
New Mexico VA Healthcare System, Albuquerque, New Mexico, United States
Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-04-08
- Target Recruit Count
- 43
- Registration Number
- NCT00223418
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 30
- Registration Number
- NCT00221416
Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00221962
- Locations
- 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 3000
- Registration Number
- NCT00216723
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
12- Week Open Label Treatment of Refractory Bipolar Depression
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-16
- Target Recruit Count
- 32
- Registration Number
- NCT00223496
- Locations
- 🇺🇸
Univ of Texas Helath Science Center at San Antonio, San Antonio, Texas, United States
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 753
- Registration Number
- NCT00216476
Abilify as an Adjunctive Treatment for Refractory Depression
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- St. Luke's-Roosevelt Hospital Center
- Target Recruit Count
- 15
- Registration Number
- NCT00220636
- Locations
- 🇺🇸
Depression Evaluation Service, NY State Psychiatric Institute, New York, New York, United States
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 30
- Registration Number
- NCT00222833
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic of UPMC, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.